8 reports of this reaction
1.5% of all EUCALYPTOL, MENTHOL, METHYL SALICYLATE, THYMOL reports
#17 most reported adverse reaction
ORAL CANDIDIASIS is the #17 most commonly reported adverse reaction for EUCALYPTOL, MENTHOL, METHYL SALICYLATE, THYMOL, manufactured by Kenvue Brands LLC. There are 8 FDA adverse event reports linking EUCALYPTOL, MENTHOL, METHYL SALICYLATE, THYMOL to ORAL CANDIDIASIS. This represents approximately 1.5% of all 537 adverse event reports for this drug.
EUCALYPTOL, MENTHOL, METHYL SALICYLATE, THYMOL has an overall safety score of 72 out of 100. Patients taking EUCALYPTOL, MENTHOL, METHYL SALICYLATE, THYMOL who experience oral candidiasis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ORAL CANDIDIASIS is a less commonly reported adverse event for EUCALYPTOL, MENTHOL, METHYL SALICYLATE, THYMOL, but still significant enough to appear in the safety profile.
In addition to oral candidiasis, the following adverse reactions have been reported for EUCALYPTOL, MENTHOL, METHYL SALICYLATE, THYMOL:
The following drugs have also been linked to oral candidiasis in FDA adverse event reports:
ORAL CANDIDIASIS has been reported as an adverse event in 8 FDA reports for EUCALYPTOL, MENTHOL, METHYL SALICYLATE, THYMOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
ORAL CANDIDIASIS accounts for approximately 1.5% of all adverse event reports for EUCALYPTOL, MENTHOL, METHYL SALICYLATE, THYMOL, making it a notable side effect.
If you experience oral candidiasis while taking EUCALYPTOL, MENTHOL, METHYL SALICYLATE, THYMOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.